Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center.
about
Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patientsExperience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseasesBiosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published EvidenceMonoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published EvidenceThe safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.CT-P13: design, development, and place in therapyEffectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.A practical guide about biosimilar data for health care providers treating inflammatory diseasesA Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab.The Role of Biosimilars in Inflammatory Bowel Disease.Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future.Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.Biosimilars in inflammatory bowel disease: A review of post-marketing experience.Emerging biologics in inflammatory bowel disease.Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease.European Experience of Infliximab Biosimilars for the Treatment of Inflammatory Bowel Disease.Comparative effectiveness of the biosimilar CT-P13.Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis.A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
P2860
Q26748630-6AE9B868-0075-49E7-8C0E-847750FB70D8Q28066776-495592E7-BAF9-47C4-9206-8EA6FC408328Q28073310-01BDC723-0A8D-4971-91A6-07EC30DCAE0BQ28078423-3667E8ED-A656-4F4F-A49A-E7CC9EEC8DE9Q30397234-4BB0B11F-9CD5-4E0C-8FC2-1A97DF519207Q33803728-A1FD0F4C-B17F-443A-A71D-B9A909475FE1Q33843746-DAC8623D-B562-437F-85DA-8A05D25BB010Q36303459-71AE7630-5FD3-42D2-BF71-A4417ABAFD5FQ37373219-7B54D8F4-1535-4833-8486-5CFCF3ECB27AQ37540190-191260D2-0D7E-49F4-8A32-41C2800F16EAQ38652276-2736B434-5BC9-41E3-90F4-83ED5CF8D665Q38786144-8CA70F4F-1F38-4C73-B7C2-38DB0341130DQ38824505-2BEA3DCF-4016-4191-ABC0-18B6B9849015Q38937842-C07E3AC1-E7AB-4ED7-A7BA-FC9C081CC500Q38977625-C73340DD-9C42-45E0-8195-6CB6F3FEC25BQ38996437-1156CCED-A916-4D2F-9A1F-69FD0EB9D40CQ39004625-9F394CC7-6874-4559-BBD4-F5247FF2C48DQ39016810-86E464DF-00C3-470A-A9AC-65D6605B359DQ39018436-C834EABB-AD76-4F42-8B82-77D12D17EBFFQ39051341-808BEAD2-713F-4EC9-A87D-8E5E16A97A00Q39359495-E0547C46-9025-4179-A075-D8CEC8E659CEQ40233716-6DF1AA50-1C85-45EE-9EC3-51017A8046A3Q41504139-01382EC8-5DC1-46C2-946A-2AC8810C5155Q47418286-1F0171DC-034B-4E5A-A7EB-0A67D93094D8Q48217871-DEAA391C-8BE0-4E2E-8887-618796C0FE02Q49596689-1BC8FB4F-0EE8-4BA3-8624-3164AE6D0296Q50073683-33D9150F-4F42-4FD7-A7D6-4F839C46A49FQ51280643-3BF75A8F-46B2-4842-8C9C-273C95ED6C41Q53341834-52099121-70B8-4EA0-B711-1B6661E93F7BQ58798380-918C5B12-D848-49FC-B999-49A4DE3C7E54
P2860
Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Efficacy of the new infliximab ...... eriences from a single center.
@en
Efficacy of the new infliximab ...... eriences from a single center.
@nl
type
label
Efficacy of the new infliximab ...... eriences from a single center.
@en
Efficacy of the new infliximab ...... eriences from a single center.
@nl
prefLabel
Efficacy of the new infliximab ...... eriences from a single center.
@en
Efficacy of the new infliximab ...... eriences from a single center.
@nl
P2093
P2860
P1476
Efficacy of the new infliximab ...... eriences from a single center.
@en
P2093
Anita Bálint
Ferenc Nagy
Klaudia Farkas
Mariann Rutka
Renáta Bor
Tamás Molnár
Zoltán Szepes
Ágnes Milassin
P2860
P304
P356
10.1517/14712598.2015.1064893
P407
P577
2015-07-02T00:00:00Z